173 related articles for article (PubMed ID: 9557928)
1. Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats.
Lacolley P; Poitevin P; Koen R; Levy BI
J Hypertens; 1998 Mar; 16(3):349-55. PubMed ID: 9557928
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats.
Nakamura Y; Ono H; Frohlich ED
Hypertension; 1999 Aug; 34(2):273-8. PubMed ID: 10454453
[TBL] [Abstract][Full Text] [Related]
3. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
[TBL] [Abstract][Full Text] [Related]
4. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Kobrin I; Charlon V; Lindberg E; Pordy R
Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
[TBL] [Abstract][Full Text] [Related]
5. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
Sarsero D; Fujiwara T; Molenaar P; Angus JA
Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
[TBL] [Abstract][Full Text] [Related]
6. Effect of the novel T-selective calcium channel antagonist mibefradil on kidney function in comparison with amlodipine.
Greven J
Arzneimittelforschung; 1998 Aug; 48(8):806-10. PubMed ID: 9748707
[TBL] [Abstract][Full Text] [Related]
7. Effect of calcium channel blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats.
Li JS; Schiffrin EL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):68-74. PubMed ID: 8797138
[TBL] [Abstract][Full Text] [Related]
8. Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats.
Vacher E; Richer C; Fornes P; Clozel JP; Giudicelli
J Cardiovasc Pharmacol; 1996 May; 27(5):686-94. PubMed ID: 8859939
[TBL] [Abstract][Full Text] [Related]
9. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
10. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay.
Major TC; Dhamija S; Black N; Liachenko S; Morenko B; Sobocinski G; Okerberg C; Tinholt P; Madore S; Kowala MC
J Pharmacol Exp Ther; 2008 Jun; 325(3):723-31. PubMed ID: 18326812
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers.
Ragueneau I; Sao AB; Démolis JL; Darné B; Funck-Brentano C; Jaillon P
Clin Pharmacol Ther; 2001 Mar; 69(3):122-9. PubMed ID: 11240976
[TBL] [Abstract][Full Text] [Related]
12. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats.
Wagner C; Krämer BK; Hinder M; Kieninger M; Kurtz A
Br J Pharmacol; 1998 Jun; 124(3):579-85. PubMed ID: 9647484
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN
Clin Ther; 1997; 19(6):1368-78. PubMed ID: 9444446
[TBL] [Abstract][Full Text] [Related]
14. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
16. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Davies GJ; Tzivoni D; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
Karam H; Clozel JP; Bruneval P; Gonzalez MF; Ménard J
Hypertension; 1999 Oct; 34(4 Pt 1):673-8. PubMed ID: 10523345
[TBL] [Abstract][Full Text] [Related]
18. Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats.
Koffi I; Lacolley P; Kirchengaast M; Pomiès JP; Laurent S; Benetos A
Eur J Pharmacol; 1998 Nov; 361(1):51-60. PubMed ID: 9851541
[TBL] [Abstract][Full Text] [Related]
19. Effect of short-term treatment of SHR with the novel calcium channel antagonist mibefradil on function of small arteries.
Li JS; Schiffrin EL
Am J Hypertens; 1997 Jan; 10(1):94-100. PubMed ID: 9008253
[TBL] [Abstract][Full Text] [Related]
20. Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine.
Yamazaki T; Komuro I; Zou Y; Kudoh S; Shiojima I; Mizuno T; Hiroi Y; Nagai R; Yazaki Y
Hypertension; 1998 Jan; 31(1):32-8. PubMed ID: 9449387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
